Detection of atovaquone-proguanil resistance conferring mutations in Plasmodium falciparum cytochrome b gene in Luanda, Angola

doi:10.1186/1475-2875-5-30

Malaria Journal
Volume 5

Viewing options:

Abstract
Full text
PDF (328KB)

Associated material:

Related literature:

Articles citing this article
on BioMed Central
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Pimentel S
Nogueira F
Benchimol C
Quinhentos V
Bom J
Varandas L
do Rosário V
Bernardino L

on PubMed

Pimentel S
Nogueira F
Benchimol C
Quinhentos V
Bom J
Varandas L
do Rosário V
Bernardino L
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Research

Detection of atovaquone-proguanil resistance conferring mutations in Plasmodium falciparum cytochrome b gene in Luanda, Angola

Sónia Pimentel¹ , Fátima Nogueira¹ , Carla Benchimol² , Vatúsia Quinhentos² , Joana Bom¹ , Luís Varandas¹^,3 , Virgílio do Rosário¹ and Luís Bernardino²

¹Centro de Malária e Outras Doenças Tropicais / IHMT / UNL, Lisbon, Portugal

²Hospital Pediátrico de Luanda, Luanda, Angola

³Unidade de Clínica das Doenças Tropicais / IHMT / UNL, Lisbon, Portugal

author email corresponding author email

Malaria Journal 2006, 5:30doi:10.1186/1475-2875-5-30


Published:	5 April 2006

Abstract

Background

The fixed dose combination atovaquone-proguanil is a recently introduced antimalarial for treatment and prophylaxis of Plasmodium falciparum malaria. It is highly effective with a good tolerability profile and a convenient prophylactic regimen. Nevertheless, cases of treatment failure have already been reported, which have been associated to mutations in the cytochrome b gene of the Plasmodium (pfcytb). The presence of atovaquone-proguanil in vivo resistance conferring mutations in pfcytb gene in Luanda, Angola, was investigated, in order to make recommendations on prescribing this antimalarial as prophylaxis for travellers.

Methods

Two hundred and forty nine blood samples from children hospitalized at Luanda Pediatric Hospital for malaria were studied. The PCR-RFLP methodology was used in order to identify pfcytb wild type codon 268 and two point mutations: T802A and A803C.

Results

All samples were identified as wild type for pfcytb gene at codon 268. In the studied population, no mutations associated to atovaquone-proguanil treatment failure were found. Prevalence of the studied mutations in the region was estimated to be less than 0.77% (99% significance level).

Conclusion

Atovaquone-proguanil can be recommended for use by travellers to Luanda with expected high efficacy. This represents an improvement compared to other currently used prophylatic antimalarials in this region. However, it is imperative to continue surveillance.